Skip to main content
. 2020 Apr 29;12(5):1108. doi: 10.3390/cancers12051108

Figure 7.

Figure 7

YAP1 expression impacts clinical significance in metastatic HER2 breast cancer patients and on trastuzumab resistance. (A) Representative IHC images of YAP1 staining from tumoral samples from two different breast cancer patients. Bar: 50 µm. (B) Representative IHC images of YAP1 staining from a paired sample, before and after treatment with trastuzumab (pre- and post-therapy). The percentage of tumor cells positively stained for YAP1 was estimated in 10% and 80%, respectively. Bar: 50 µm. (C) YAP1 expression levels in pre- and post-treatment settings in metastatic cases; n = 19. Dashed lines represent cases with no significant variation. (D) Id. in neoadjuvant setting; n = 24. (E) Kaplan-Meier analysis of PFS and (F) OS in the cohort of 58 HER2-positive metastatic breast cancer patients. YAP1 overexpression (dashed line) was associated with lower PFS (p < 0.001) and OS (p < 0.001). (G) Kaplan-Meier analysis of PFS and (H) OS in the same cohort of 58 HER2-positive metastatic breast cancer patients with respect to TAZ overexpression (dashed line). TAZ was associated with lower PFS (p = 0.020) and OS (p = 0.024).